From MarketBeat:

Shares of Intra-Cellular Therapies, Inc. have an average “Buy” recommendation from ten analysts. The average 12-month target price is $80.45. The stock is currently trading at $69.04. In the last quarter, the company beat EPS estimates by $0.34 and had revenue of $126.17 million. Insiders have sold 125,937 shares of company stock valued at $8,137,462. 3.40% of the stock is owned by insiders. 86.94% of the stock is owned by institutional investors.

Intra-Cellular Therapies is a biopharmaceutical company focusing on the development and commercialization of small molecule drugs for neuropsychiatric and neurological disorders in the United States. The company has recently been trading at $69.04 after beating EPS estimates in the last quarter and having revenue of $126.17 million.

Insiders and institutional investors have been actively trading shares of Intra-Cellular Therapies. Insiders have sold 125,937 shares of company stock valued at $8,137,462. 3.40% of the stock is owned by insiders. 86.94% of the stock is currently owned by institutional investors.

The company focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system. This could potentially lead to future growth and development for the company.



Read more: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of “Buy” by Analysts